AJD 101
Alternative Names: AJD101Latest Information Update: 02 Dec 2008
At a glance
- Originator Ajinomoto
- Developer Daiichi Sankyo Company
- Class Antihyperglycaemics
- Mechanism of Action Glucose stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 02 Dec 2008 Discontinued - Phase-I for Type-2 diabetes mellitus in European Union (PO)
- 02 Dec 2008 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO)
- 02 Dec 2008 Discontinued - Phase-II for Type-2 diabetes mellitus in Japan (PO)